Novel insights into molecular chaperone regulation of ribonucleotide reductase

Area of Science:

• Molecular biology
• Cancer research
• Biochemistry

Background:

• Molecular chaperones Hsp70 and Hsp90 regulate protein folding and stability, crucial for cellular function.
• These chaperones are implicated in the stability of disease-related proteins, including those in cancer.
• Current ribonucleotide reductase (RNR) inhibitors for cancer treatment can cause severe side effects.

Purpose of the Study:

• To explore chaperone inhibition as a strategy to sensitize cancer cells to RNR inhibitors.
• To investigate the potential for developing less toxic anti-cancer therapies targeting the RNR complex.

Main Methods:

• Investigated the interaction between molecular chaperones (Hsp70, Hsp90) and the oncogenic ribonucleotide reductase (RNR) complex.
• Examined the effects of chaperone inhibition on RNR subunit stability in cancer cells and model organisms (budding yeast).
• Assessed the impact of chaperone inhibition on cancer cell sensitivity to RNR inhibitors.

Main Results:

• Chaperone inhibition leads to the destabilization of RNR subunits.
• Cancer cells and budding yeast treated with chaperone inhibitors show increased sensitivity to RNR inhibitors.
• This suggests a potential mechanism to overcome resistance to existing RNR-targeted cancer therapies.

Conclusions:

• Inhibiting molecular chaperones Hsp70 and Hsp90 destabilizes the RNR complex.
• This chaperone-RNR interaction offers a novel strategy to target cancer cells resistant to standard RNR inhibitors.
• Developing chaperone-based therapies could lead to more potent and less toxic anti-cancer treatments.